Aarti Drugs Buyback will open for subscription from 27 April 2021. the company aims for an issue size of ₹60 Crores through this buyback issue.
Aarti Drugs Limited
AD Limited is one of the leading pharma companies in India. The company manufactures over 40 products comprising of bulk actives, key intermediates, and specialty chemicals. Its product portfolio includes anti-biotic, antiprotozoal, anti-inflammatory, anti-fungal, anti-diabetic, cardio-protectant, vitamins, anti-arthritis, sedatives therapeutic groups that help in lifesaving and lifestyle-related diseases. The Company has nine manufacturing locations located at Tarapur (Maharashtra) and two manufacturing locations located at Sarigam (Gujarat), most of them being GMP certified. The company exports its products to over 100 countries worldwide.
Objects of the Issue
- Improve Return on Equity.
- Service the equity more efficiently.
- Improve earnings per share and thus increase the shareholder’s value in the long-term.
- Return surplus cash to the shareholders.
Aarti Drugs Buyback Issue Timetable
| Offer Opens On | 27 April 2021 |
| Offer Closes On | 10 May 2021 |
| Record Date | 01 April2021 |
| Last Date for receipt of Tender Forms | 12 May 2021 |
| Finalisation of Buyback Acceptance | 19 May 2021 |
| Last Date for settlment of bids | 20 May 2021 |
| Last Date for Extinguishment of Shares | 27 May 2021 |
Aarti Drugs Buyback Details
| Security Name | Aarti Drugs Limited |
| Issue Type | Tender Offer |
| Issue Size (Shares) | 0.06 Crores |
| Issue Size (Amount) | ₹60.00 Crores |
| Buyback Price | ₹1000 per share |
| Face Value | ₹10 per share |
| Listing At | BSE, NSE |
Buyback Ratio
| Category | Entitlement Ratio of Buyback |
|---|---|
| Reserved Category for Small Shareholders | 8 Equity Shares out of every 569 paid-up Equity Shares held on the Record Date. |
| General Category for all other Eligible Shareholders | 5 Equity Shares out of every 851 paid-up Equity Shares held on the Record Date. |
Company Financials
| Particulars | For the year/period ended (Rs. in Millions) | ||
|---|---|---|---|
| 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
| Total Income | 18,075.71 | 15,671.17 | 12,636.18 |
| Profit After Tax | 1,413.99 | 897.52 | 823.07 |
| Net Worth | 6,467.45 | 5,373.09 | 4,502.79 |
Stock Market Data (for preceding 3 months)
BSE
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Feb-2021 | 694.95 | 625 | 658.87 |
| Jan-2021 | 755.5 | 670.05 | 710.03 |
| Dec-2021 | 812 | 645 | 741.25 |
NSE
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Month | High Price | Low Price | Average Price |
| Feb-2021 | 695 | 628 | 658.75 |
| Jan-2021 | 756 | 670 | 710.11 |
| Dec-2021 | 811 | 645.65 | 741.17 |
Aarti Drugs Buyback Registrar
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083
Phone: +91-22-4918 6270
Email: aartidrugs.buyback2021@linkintime.co.in
Website: http://www.linkintime.co.in
Company Contact Information
Aarti Drugs Limited
Plot No. – N-198,
M.I.D.C., Village – Pamtermbhi
Taluka & Dist. Palghar – 401 506
Phone: +91 22 2404 8199
Email: investorrelations@aartidrugs.com
Website: https://www.aartidrugs.co.in/
Final Thoughts
A buyback occurs when the issuing company pays shareholders the market value per share and re-absorbs that portion of its ownership that was previously distributed among public and private investors. subscribing for a buyback issue is purely a personal choice. make a detailed study before you make a decision on buyback issue subscription.
Happy Investing